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EV06 Trial: Modulation of the Immunogenicity 
of the DNA-HIV-PT123 and AIDSVAX®B/E 
combination HIV vaccine in adult Ugandans by 
S. mansoni Infection  
Pietro Pala1, Jonathan Levin1, Annet Nanvubya2, Freddie Kibengo1, 
Annemarie Namuniina2, Paul Kitandwe2, Jennifer Serwanga1, 
Nicole Yates3, Bryan Mayer4, David Montefiori3, Georgia Tomaras3, 
Merlin Robb5, Carter Lee6, Ralf Wagner7, Dani Vooijs8, Kundai 
Chinyenze8, Frances Priddy8, Song Ding9, Giuseppe Pantaleo10, 
Pontiano Kaleebu1, and the EV06 Study Teams 
1MRC/UVRI Uganda Research Unit on AIDS, Uganda, 2UVRI-
IAVI HIV Vaccine Program, Uganda, 3Duke University Medical 
Center, United States, 4Fred Hutchinson Cancer Research 
Center, United States, 5U.S. Military HIV Research Program, 
United States, 6Global Solutions for Infectious Diseases 
(GSID), United States, 7Universität Regensburg, Germany, 
8International AIDS Vaccine Initiative (IAVI), United States, 
9EuroVacc Foundation, Switzerland, 10Centre Hospitalier 
Universitaire Vaudois (CHUV), Switzerland  
Background: The prevalence of S. mansoni (SM) in Sub Saharan 
Africa raises concerns on the worm´s effects on the response 
to vaccines. We investigated the impact of SM infection on the 
humoral response to a novel DNA vaccine expressing Clade C 
Env, Gag and PolNef co-administered with AIDSVAX B/E. 
Methods: This randomized double blind trial enrolled 72 male 
and female Ugandans aged 18-45, 36 infected with S. mansoni 
(SM+) and 36 uninfected (SM-). In each arm 30 received vaccine 
and 6 placebo at week 0, 4 and 24. Responses were evaluated 
at week 0, 6, 26 and 36. Humoral responses were measured by 
binding and neutralization assays. IgG against a panel of HIV-1 
envelope glycoproteins were measured by BAMA. Neutralizing 
antibodies (Nabs) were measured using TZM/bl cells and tier 
1 pseudoviruses. 
Results: Significant differences in binding IgG response rates 
were observed against the vaccine matched clade C V1V2 
(gp70-96ZM651.02 V1V2) at week 6: 56% among SM+ vaccinated 
participants compared to 86% among SM- vaccinated participants 
(P = 0.039). At week 36, response magnitudes were also 
statistically lower in the SM+ group against the clade C vaccine 
matched gp120 and gp140 proteins (P = 0.04 for both). Response 
rates between groups were tested using Fisher‘s exact test and 
magnitudes using the Wilcoxon sum-rank test. Furthermore, 
vaccinated SM+ participants had: 1) significantly lower Nab 
response rates at week 36 for Clade C MW965.26 and Clade A/E 
TH023.6 (P < 0.05); 2) significantly lower IC50 titers for MW965.26 
and TH023.6 at both weeks 26 and 36; and 3) lower median AUC-
MB at each study week, which was statistically significantly 
different at week 36. 
Conclusions: This DNA/gp120 protein vaccine regimen induced 
strong gp120, gp140 and V1V2 region-focused binding IgG and 
Nab responses. Preliminary evidence that S.mansoni infection may 
modulate antibody responses induced by vaccination is provided.
Poster Discussion 01: Evaluation of Vaccine Concepts
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